

Supporting Information for

**Diastereoselective Synthesis of Functionalized Tetrahydropyridazines Containing
Indole Scaffolds *via* Inverse-Electron-Demand Aza-Diels–Alder Reaction**

Taotao Chen,^a Chao Che,^a Zhefei Guo,^a Xiu-Qin Dong,^{*ac} Chun-Jiang Wang^{*ab}

^a Engineering Research Center of Organosilicon Compounds & Materials, Ministry of Education, College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, Hubei, 430072, P. R. China.

^b Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China.

^c Suzhou Institute of Wuhan University, Suzhou, Jiangsu, 215123, P. R. China.

E-mail address: cjwang@whu.edu.cn; xiuqindong@whu.edu.cn.

Table of Contents


I.	General remarks.....	S2
II.	General procedure for the inverse electron-demand aza-Diels-Alder reaction.....	S2
III.	Optimization reaction conditions for the asymmetric IEDDA cyclization.....	S14
IV.	Gram-scale inverse-electron-demand aza-Diels-Alder reaction.....	S15
V.	Synthetic transformation.....	S16
VI.	The configuration determination of <i>trans</i> - 3b	S17
VII.	Reference.....	S18
VIII.	¹ H NMR and ¹³ C NMR spectra.....	S20
IX.	HPLC spectra.....	S47

I. General remarks

¹H NMR spectra were recorded on a Bruker 400 MHz spectrometer in CDCl₃. Chemical shifts are reported in ppm with the internal TMS signal at 0.0 ppm as a standard. The data are reported as (s = single, d = double, t = triple, q = quarte, m = multiple or unresolved, brs = broad single, coupling constant(s) in Hz, integration). ¹³C NMR spectra were recorded on a Bruker 100 MHz spectrometer in CDCl₃. Chemical shifts are reported in ppm with the internal chloroform signal at 77.0 ppm as a standard. Commercially obtained reagents were used without further purification. Solvents were purified prior to use according to the standard methods. Unless otherwise noted, all reactions were carried out under nitrogen atmosphere. All reactions were monitored by TLC with silica gel coated plates. Enantiomeric ratios were determined by chiral-phase HPLC analysis in comparison with authentic racemic materials using a chiralpak IE column. High Resolution Mass Spectra were recorded using ESI-TOF technique. 3-Vinylindoles,¹ azoalkenes,² were prepared according to the literature procedure.

II. General procedure for the inverse electron-demand aza-Diels–Alder reaction

A flame dried Schlenck tube was cooled to room temperature and filled with N₂. 3-vinylindoles (0.28 mmol), the azoalkene generating *in situ* from benzohydrazide (0.20 mmol), Na₂CO₃ (0.48 mmol) and CH₃CN (2.0 mL) were added into the Schlenck tube and filled with N₂ at room temperature. TLC analysis indicated completion of the reaction after about 30 h. Then the reaction mixture was concentrated *in vacuo* to obtain the crude product. The crude product was purified by flash silica gel chromatography to afford the product.




***Trans*-(6-(1-methyl-1*H*-indol-3-yl)-3,5-diphenyl-5,6-dihydropyridazin-1(4*H*)-yl)(phenyl)-methanone (3a):**

Yield (87%); 81 mg; White solid; m.p. 239-241 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.82 (d, *J*=


7.8 Hz, 1H), 7.69-7.66 (m, 4H), 7.47 – 7.39 (m, 4H), 7.38 – 7.33 (m, 6H), 7.30 – 7.25 (m, 3H), 7.23 – 7.21 (m, 1H), 6.75 (s, 1H), 6.37 (s, 1H), 4.02 (d, $J = 7.2$ Hz, 1H), 3.66 (s, 3H), 2.95 (d, $J = 18.3$ Hz, 1H), 2.83 (dd, $J = 18.3, 7.0$ Hz, 1H). ^{13}C NMR (100 MHz, Chloroform- d) δ 170.3, 146.4, 142.3, 137.7, 137.1, 135.2, 130.3, 129.9, 129.4, 128.9, 128.5, 127.4, 127.2, 126.9, 126.1, 125.5, 125.2, 122.0, 119.4, 118.9, 113.2, 109.7, 52.1, 38.5, 32.8, 24.7. HRMS (ESI-TOF) Calcd. For $\text{C}_{32}\text{H}_{28}\text{N}_3\text{O}$ ($[\text{M}+\text{H}]^+$): 470.2227, found: 470.2212.

opt-3a: Yield (81%); 75 mg; $[\alpha]_{\text{D}}^{20} = -27.2$ (c 1.0, CHCl_3); >20:1 dr, it was determined by the crude ^1H NMR analysis. The product was analyzed by HPLC to determine the enantiomeric excess: 93% ee (Chiralpak IE, i -propanol/hexane = 40/60, flow rate 1.2 mL/min, $\lambda = 230$ nm); $t_{\text{r}} = 28.7$ and 34.0 min.




Trans-(2-methoxyphenyl)(6-(1-methyl-1H-indol-3-yl)-3,5-diphenyl-5,6-dihydropyridazin-1(4H)-yl)methanone (3b):

Yield (84%); 83 mg; White solid; m.p. 189-190 °C; ^1H NMR (400 MHz, Chloroform- d) δ 7.79 (d, $J = 9.3$ Hz, 1H), 7.47 – 7.46 (m, 1H), 7.45-7.43 (m, 1H), 7.41 – 7.37 (m, 3H), 7.36 – 7.25 (m, 9H), 7.25 – 7.19 (m, 1H), 7.00-6.96 (m, 2H), 6.89 (s, 1H), 6.40 (s, 1H), 4.00 (d, $J = 7.0$ Hz, 1H), 3.79 (s, 3H), 3.69 (s, 3H), 2.84 (d, $J = 18.1$ Hz, 1H), 2.74 (dd, $J = 18.1, 7.0$ Hz, 1H). ^{13}C NMR (100 MHz, Chloroform- d) δ 170.4, 156.0, 145.4, 142.6, 137.9, 137.4, 130.2, 129.1, 128.8, 128.4, 128.2, 127.4, 127.2, 127.1, 126.7, 125.34, 125.31, 121.9, 120.4, 119.3, 119.0, 113.5, 110.5, 109.7, 55.5, 51.3, 38.3, 32.9, 25.0. HRMS (ESI-TOF) Calcd. For $\text{C}_{33}\text{H}_{30}\text{N}_3\text{O}_2$ ($[\text{M}+\text{H}]^+$): 500.2333, found: 500.2322.




Trans-(6-(1-methyl-1H-indol-3-yl)-3,5-diphenyl-5,6-dihydropyridazin-1(4H)-yl)(*m*-tolyl)methanone (3c):

Yield (86%); 83 mg; White solid; m.p. 168-170 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 7.88 (d, $J = 7.8$ Hz, 1H), 7.73 (t, $J = 3.7$ Hz, 2H), 7.58 (s, 1H), 7.54 (d, $J = 7.0$ Hz, 1H), 7.44 – 7.38 (m, 7H), 7.37 – 7.27 (m, 6H), 6.81 (s, 1H), 6.43 (s, 1H), 4.07 (d, $J = 7.2$ Hz, 1H), 3.70 (s, 3H), 2.98 (d, $J = 18.3$ Hz, 1H), 2.88 (dd, $J = 18.2, 6.9$ Hz, 1H), 2.45 (s, 3H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 170.4, 146.1, 142.3, 137.6, 137.1, 137.0, 135.1, 130.9, 130.5, 129.3, 128.8, 128.4, 127.13, 127.10, 126.9, 126.0, 125.5, 125.2, 122.0, 119.3, 118.9, 113.2, 109.6, 52.0, 38.4, 32.7, 24.7, 21.4. HRMS (ESI-TOF) Calcd. For $\text{C}_{33}\text{H}_{30}\text{N}_3\text{O}$ ($[\text{M}+\text{H}]^+$): 484.2383, found: 484.2375.



***Trans*-(4-bromophenyl)(6-(1-methyl-1*H*-indol-3-yl)-3,5-diphenyl-5,6-dihydropyridazin-1(4*H*)-yl)methanone (3d):**


Yield (81%); 89 mg; White solid; m.p. 190-192 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 7.81 (d, $J = 7.9$ Hz, 1H), 7.67 (dd, $J = 7.9, 2.9$ Hz, 2H), 7.55 (s, 4H), 7.41 – 7.33 (m, 7H), 7.32 – 7.25 (m, 3H), 7.23 – 7.20 (m, 1H), 6.73 (s, 1H), 6.34 (s, 1H), 4.00 (d, $J = 7.3$ Hz, 1H), 3.66 (s, 3H), 2.96 (d, $J = 18.4$ Hz, 1H), 2.84 (dd, $J = 18.3, 7.0$ Hz, 1H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 169.3, 147.1, 142.2, 137.7, 136.9, 134.0, 131.7, 130.7, 129.6, 129.0, 128.7, 127.3, 126.9, 126.0, 125.6, 125.2, 124.9, 122.1, 119.5, 118.9, 113.1, 109.8, 52.3, 38.5, 32.9, 24.7. HRMS (ESI-TOF) Calcd. For $\text{C}_{32}\text{H}_{26}\text{BrN}_3\text{ONa}$ ($[\text{M}+\text{Na}]^+$): 570.1151, found: 570.1136.



***Trans*-(4-chlorophenyl)(6-(1-methyl-1*H*-indol-3-yl)-3,5-diphenyl-5,6-dihydropyridazin-1(4*H*)-yl)methanone (3e):**


Yield (82%); 82 mg; White solid; m.p. 210-212 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 7.73 (d, $J = 7.6$ Hz, 1H), 7.59 (dd, $J = 7.6, 2.9$ Hz, 2H), 7.55 (d, $J = 8.3$ Hz, 2H), 7.31 – 7.26 (m, 9H), 7.25 – 7.16

(m, 3H), 7.13 – 7.10 (m, 1H), 6.65 (s, 1H), 6.27 (s, 1H), 3.92 (d, $J = 7.3$ Hz, 1H), 3.57 (s, 3H), 2.88 (d, $J = 18.3$ Hz, 1H), 2.75 (dd, $J = 18.4, 7.0$ Hz, 1H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 169.1, 146.9, 142.1, 137.6, 136.9, 136.4, 133.5, 131.5, 129.5, 128.9, 128.6, 127.6, 127.2, 126.8, 125.9, 125.5, 125.2, 122.1, 119.4, 118.8, 113.0, 109.7, 52.3, 38.4, 32.8, 24.7. HRMS (ESI-TOF) Calcd. For $\text{C}_{32}\text{H}_{27}\text{ClN}_3\text{O}$ ($[\text{M}+\text{H}]^+$): 504.1837, found: 504.1825.



***Trans*-methyl 6-(1-methyl-1*H*-indol-3-yl)-3,5-diphenyl-5,6-dihydropyridazine-1(4*H*)-carboxylate (3f):**


Yield (86%); 72 mg; White solid; m.p. 220-222 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 7.89 (dd, $J = 7.9, 1.8$ Hz, 2H), 7.78 (d, $J = 7.9$ Hz, 1H), 7.46 – 7.40 (m, 3H), 7.36 – 7.27 (m, 7H), 7.25 – 7.20 (m, 1H), 6.83 (s, 1H), 5.99 (s, 1H), 3.87 (d, $J = 7.2$ Hz, 1H), 3.81 (s, 3H), 3.70 (s, 3H), 2.88 (d, $J = 18.3$ Hz, 1H), 2.77 (dd, $J = 18.3, 7.1$ Hz, 1H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 155.2, 147.1, 142.5, 137.52, 137.46, 129.3, 128.9, 128.5, 127.1, 126.9, 125.9, 125.6, 125.1, 122.0, 119.3, 118.7, 114.1, 109.7, 53.8, 53.7, 38.7, 32.8, 24.5. HRMS (ESI-TOF) Calcd. For $\text{C}_{27}\text{H}_{26}\text{N}_3\text{O}_2$ ($[\text{M}+\text{H}]^+$): 424.2020, found: 424.2010.



***Trans*-tert-butyl 6-(1-methyl-1*H*-indol-3-yl)-3,5-diphenyl-5,6-dihydropyridazine-1(4*H*)-carboxylate (3g):**


Yield (84%); 78 mg; White solid; m.p. 159-160 °C; ^1H NMR (400 MHz, Chloroform-*d*) δ 7.93 (d, $J = 8.0$ Hz, 2H), 7.77 (d, $J = 7.2$ Hz, 1H), 7.46 – 7.39 (m, 3H), 7.38 – 7.28 (m, 7H), 7.24 (d, $J = 7.9$ Hz, 1H), 6.86 (s, 1H), 5.96 (s, 1H), 3.86 (d, $J = 6.8$ Hz, 1H), 3.70 (s, 3H), 2.83 (d, $J = 18.2$ Hz, 1H), 2.79 (dd, $J = 17.7, 6.2$ Hz, 1H), 1.43 (s, 9H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 153.4, 146.1, 142.9,

137.6, 137.4, 129.0, 128.7, 128.3, 126.93, 126.88, 126.0, 125.5, 125.2, 121.8, 119.2, 118.6, 114.4, 109.6, 81.3, 53.4, 38.8, 32.7, 28.1, 24.4. HRMS (ESI-TOF) Calcd. For $C_{30}H_{32}N_3O_2$ ($[M+H]^+$): 466.2489, found: 466.2481.



***Trans*-(3-(4-fluorophenyl)-6-(1-methyl-1*H*-indol-3-yl)-5-phenyl-5,6-dihydropyridazin-1(4*H*)-yl)-(phenyl)methanone (3h):**


Yield (80%); 78 mg; White solid; m.p. 217-218 °C; 1H NMR (400 MHz, Chloroform-*d*) δ 7.81 (d, J = 7.9 Hz, 1H), 7.66 – 7.61 (m, 4H), 7.47 – 7.41 (m, 3H), 7.36 (d, J = 5.0 Hz, 4H), 7.30 – 7.26 (m, 3H), 7.23 – 7.18 (m, 1H), 7.02 (t, J = 8.6 Hz, 2H), 6.74 (s, 1H), 6.36 (s, 1H), 4.01 (d, J = 7.0 Hz, 1H), 3.67 (s, 3H), 2.90 (d, J = 18.2 Hz, 1H), 2.80 (dd, J = 18.2, 6.9 Hz, 1H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 170.3, 163.5 (d, J = 248.2 Hz), 145.4, 142.2, 137.7, 135.2, 133.3 (d, J = 3.1 Hz), 130.3, 129.9, 129.0, 127.5, 127.4, 127.3, 126.9, 126.0, 125.2, 122.1, 119.4, 119.0, 115.5 (d, J = 21.6 Hz), 113.1, 109.7, 52.1, 38.4, 32.9, 24.8. HRMS (ESI-TOF) Calcd. For $C_{32}H_{27}FN_3O$ ($[M+H]^+$): 488.2133, found: 488.2122.



***Trans*-(3-(4-chlorophenyl)-6-(1-methyl-1*H*-indol-3-yl)-5-phenyl-5,6-dihydropyridazin-1(4*H*)-yl)-(phenyl)methanone (3i):**


Yield (78%); 78 mg; White solid; m.p. 229-230 °C; 1H NMR (400 MHz, Chloroform-*d*) δ 7.81 (d, J = 7.9 Hz, 1H), 7.65 (d, J = 7.4 Hz, 2H), 7.58 (d, J = 8.8 Hz, 2H), 7.49 – 7.38 (m, 3H), 7.35 – 7.33 (m,

4H), 7.32 – 7.24 (m, 5H), 7.15-7.13 (m, 1H), 6.73 (s, 1H), 6.36 (s, 1H), 4.01 (d, $J = 7.1$ Hz, 1H), 3.66 (s, 3H), 2.89 (d, $J = 18.2$ Hz, 1H), 2.79 (dd, $J = 18.2, 6.9$ Hz, 1H). ^{13}C NMR (100 MHz, Chloroform- d) δ 170.3, 145.2, 142.1, 137.7, 135.5, 135.3, 135.1, 130.3, 129.8, 128.9, 128.7, 127.4, 127.3, 126.8, 126.7, 125.9, 125.1, 122.1, 119.4, 118.9, 113.1, 109.7, 52.1, 38.3, 32.8, 24.6. HRMS (ESI-TOF) Calcd. For $\text{C}_{32}\text{H}_{27}\text{ClN}_3\text{O}$ ($[\text{M}+\text{H}]^+$): 504.1837, found: 504.1826.



***Trans*-(3-(4-bromophenyl)-6-(1-methyl-1*H*-indol-3-yl)-5-phenyl-5,6-dihydropyridazin-1(4*H*)-yl)(phenyl)methanone (3j):**


Yield (84%); 92 mg; White solid; m.p. 238-240 °C; ^1H NMR (400 MHz, Chloroform- d) δ 7.81 (d, $J = 7.8$ Hz, 1H), 7.64 (d, $J = 7.4$ Hz, 2H), 7.53 – 7.46 (m, 6H), 7.41 (t, $J = 7.3$ Hz, 2H), 7.36 – 7.35 (m, 4H), 7.31 – 7.28 (m, 2H), 7.23 – 7.19 (m, 1H), 6.73 (s, 1H), 6.36 (s, 1H), 4.01 (d, $J = 7.1$ Hz, 1H), 3.68 (s, 3H), 2.89 (d, $J = 18.2$ Hz, 1H), 2.79 (dd, $J = 18.3, 6.9$ Hz, 1H). ^{13}C NMR (100 MHz, Chloroform- d) δ 170.4, 145.3, 142.1, 137.7, 136.0, 135.1, 131.7, 130.4, 129.9, 129.0, 127.5, 127.3, 127.0, 126.8, 126.0, 125.2, 123.7, 122.1, 119.4, 118.9, 113.1, 109.7, 52.2, 38.4, 32.9, 24.6. HRMS (ESI-TOF) Calcd. For $\text{C}_{32}\text{H}_{27}\text{BrN}_3\text{O}$ ($[\text{M}+\text{H}]^+$): 548.1332, found: 548.1316.



***Trans*-(6-(1*H*-indol-3-yl)-3,5-diphenyl-5,6-dihydropyridazin-1(4*H*)-yl)(phenyl)methanone (3k):**


Yield (80%); 72 mg; White solid; m.p. 182-183 °C; ^1H NMR (400 MHz, Chloroform- d) δ 8.23 (s, 1H), 7.82 (d, $J = 8.8$ Hz, 1H), 7.66 – 7.62 (m, 4H), 7.50 – 7.40 (m, 3H), 7.40 – 7.32 (m, 7H), 7.31 – 7.27 (m, 2H), 7.24 – 7.18 (m, 2H), 6.80 (d, $J = 1.5$ Hz, 1H), 6.40 (s, 1H), 4.01 (d, $J = 5.4$ Hz, 1H), 2.94 (d, $J =$

18.3 Hz, 1H), 2.78 (dd, $J = 18.3, 7.1$ Hz, 1H). ^{13}C NMR (100 MHz, Chloroform- d) δ 170.4, 146.5, 142.2, 137.0, 136.9, 135.2, 130.2, 129.8, 129.4, 128.9, 128.5, 127.4, 127.2, 126.8, 125.5, 124.7, 122.3, 121.5, 119.7, 118.6, 114.6, 111.6, 52.1, 38.3, 24.7. HRMS (ESI-TOF) Calcd. For $\text{C}_{31}\text{H}_{26}\text{N}_3\text{O}$ ($[\text{M}+\text{H}]^+$): 456.2070, found: 456.2061.



***Trans*-(6-(1-benzyl-1*H*-indol-3-yl)-3,5-diphenyl-5,6-dihydropyridazin-1(4*H*)-yl)(phenyl)methanone (3l):**


Yield (83%); 90 mg; White solid; m.p. 160-161 °C; ^1H NMR (400 MHz, Chloroform- d) δ 7.84 – 7.82 (m, 1H), 7.67 – 7.59 (m, 4H), 7.47 – 7.30 (m, 10H), 7.27 – 7.21 (m, 3H), 7.20 – 7.14 (m, 4H), 6.99 – 6.94 (m, 2H), 6.86 (s, 1H), 6.41 (s, 1H), 5.23 – 5.10 (m, 2H), 4.02 (d, $J = 7.3$ Hz, 1H), 2.92 (d, $J = 18.3$ Hz, 1H), 2.80 (dd, $J = 18.3, 7.1$ Hz, 1H). ^{13}C NMR (100 MHz, Chloroform- d) δ 170.3, 146.6, 142.2, 137.2, 137.1, 135.2, 130.2, 129.8, 129.3, 128.9, 128.6, 128.4, 127.5, 127.3, 127.2, 126.9, 126.5, 125.7, 125.5, 125.4, 122.2, 119.6, 119.0, 113.8, 110.2, 52.0, 50.0, 38.5, 24.9. HRMS (ESI-TOF) Calcd. For $\text{C}_{38}\text{H}_{32}\text{N}_3\text{O}$ ($[\text{M}+\text{H}]^+$): 546.2540, found: 546.2530.



***Trans*-(6-(1-methyl-1*H*-indol-3-yl)-3-phenyl-5-(*m*-tolyl)-5,6-dihydropyridazin-1(4*H*)-yl)-(phenyl)methanone (3m):**


Yield (84%); 80 mg; White solid; m.p. 148-150 °C; ^1H NMR (400 MHz, Chloroform- d) δ 7.82 (d, $J = 7.8$ Hz, 1H), 7.70 – 7.65 (m, 4H), 7.49 – 7.38 (m, 3H), 7.35 – 7.21 (m, 8H), 7.13-7.05 (m, 2H), 6.74 (s, 1H), 6.34 (s, 1H), 3.97 (d, $J = 7.2$ Hz, 1H), 3.64 (s, 3H), 2.91 (d, $J = 18.3$ Hz, 1H), 2.81 (dd, $J = 18.3, 7.0$ Hz, 1H), 2.35 (s, 3H). ^{13}C NMR (100 MHz, Chloroform- d) δ 170.3, 146.5, 142.3, 138.4, 137.6, 137.1, 135.3, 130.2, 129.9, 129.3, 128.7, 128.4, 127.94, 127.91, 127.3, 126.0, 125.5, 125.2, 123.5,

122.0, 119.3, 118.9, 113.2, 109.6, 52.1, 38.4, 32.7, 24.9, 21.6. HRMS (ESI-TOF) Calcd. For C₃₃H₃₀N₃O ([M+H]⁺): 484.2383, found: 484.2375.




***Trans*-(6-(1-methyl-1*H*-indol-3-yl)-3-phenyl-5-(*p*-tolyl)-5,6-dihydropyridazin-1(4*H*)-yl)-(phenyl)methanone (3n):**

Yield (89%); 85 mg; White solid; m.p. 190-191 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.81 (d, *J* = 7.8 Hz, 1H), 7.70 – 7.64 (m, 4H), 7.45 – 7.39 (m, 3H), 7.33 – 7.19 (m, 8H), 7.14 (d, *J* = 7.9 Hz, 2H), 6.74 (s, 1H), 6.35 (s, 1H), 3.97 (d, *J* = 7.4 Hz, 1H), 3.62 (s, 3H), 2.90 (d, *J* = 18.3 Hz, 1H), 2.80 (dd, *J* = 18.3, 7.0 Hz, 1H), 2.30 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 170.3, 146.4, 139.2, 137.6, 137.1, 136.7, 135.2, 130.2, 129.9, 129.5, 129.3, 128.4, 127.3, 126.7, 126.0, 125.5, 125.2, 121.9, 119.3, 118.9, 113.2, 109.6, 52.1, 38.0, 32.7, 24.8, 21.0. HRMS (ESI-TOF) Calcd. For C₃₃H₃₀N₃O ([M+H]⁺): 484.2383, found: 484.2373.




***Trans*-(6-(1-methyl-1*H*-indol-3-yl)-3-phenyl-5-(4-(trifluoromethyl)phenyl)-5,6-dihydropyridazin-1(4*H*)-yl)(phenyl)methanone (3o):**

Yield (80%); 85 mg; White solid; m.p. 189-191 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.79 (d, *J* = 7.9 Hz, 1H), 7.71 – 7.65 (m, 4H), 7.61 – 7.56 (m, 2H), 7.51 – 7.40 (m, 5H), 7.38 – 7.25 (m, 5H), 7.24 – 7.19 (m, 1H), 6.77 (s, 1H), 6.39 (s, 1H), 4.06 (d, *J* = 6.5 Hz, 1H), 3.66 (s, 3H), 2.93 (d, *J* = 18.2 Hz, 1H), 2.86 (dd, *J* = 18.3, 6.5 Hz, 1H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 170.3, 146.3, 145.9, 137.7, 136.8, 134.9, 130.4, 129.9, 129.5 (q, *J* = 32.4 Hz), 128.6, 127.5, 127.4, 126.1, 125.9 (q, *J* = 3.7 Hz), 125.5, 125.1, 124.0 (q, *J* = 270.0 Hz), 122.1, 119.5, 118.7, 112.7, 109.8, 51.6, 38.4, 32.8, 24.6. HRMS (ESI-TOF) Calcd. For C₃₃H₂₇F₃N₃O ([M+H]⁺): 538.2101, found: 538.2087.




***Trans*-(5-(4-chlorophenyl)-6-(1-methyl-1*H*-indol-3-yl)-3-phenyl-5,6-dihydropyridazin-1(4*H*)-yl)(phenyl)methanone (3p):**

Yield (80%); 80 mg; White solid; m.p. 174-176 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.78 (d, *J* = 7.9 Hz, 1H), 7.71 – 7.63 (m, 4H), 7.50 – 7.39 (m, 3H), 7.34 – 7.30 (m, 4H), 7.29 – 7.17 (m, 6H), 6.73 (s, 1H), 6.34 (s, 1H), 3.97 – 3.94 (m, 1H), 3.64 (s, 3H), 2.88 (d, *J* = 18.3 Hz, 1H), 2.81 (dd, *J* = 18.3, 6.5 Hz, 1H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 169.3, 145.0, 139.7, 136.6, 135.9, 134.0, 131.9, 129.4, 128.9, 128.5, 128.0, 127.5, 127.3, 126.4, 125.0, 124.5, 124.1, 121.1, 118.4, 117.8, 111.8, 108.7, 50.9, 36.9, 31.8, 23.7. HRMS (ESI-TOF) Calcd. For C₃₂H₂₇ClN₃O ([M+H]⁺): 504.1837, found: 504.1826.




***Trans*-(5-(4-bromophenyl)-6-(1-methyl-1*H*-indol-3-yl)-3-phenyl-5,6-dihydropyridazin-1(4*H*)-yl)(phenyl)methanone (3q):**

Yield (78%); 85 mg; White solid; m.p. 184-185 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.77 (d, *J* = 5.3 Hz, 1H), 7.69 – 7.64 (m, 4H), 7.47 – 7.41 (m, 5H), 7.35 – 7.21 (m, 7H), 7.20 (dd, *J* = 6.6, 1.6 Hz, 1H), 6.74 (s, 1H), 6.35 (s, 1H), 3.96 (d, *J* = 4.5 Hz, 1H), 3.64 (s, 3H), 2.88 (d, *J* = 16.5 Hz, 1H), 2.81 (dd, *J* = 18.3, 6.5 Hz, 1H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 170.2, 146.0, 141.2, 137.6, 136.8, 135.0, 131.9, 130.4, 129.9, 129.5, 128.6, 128.5, 127.4, 126.0, 125.4, 125.1, 122.0, 121.0, 119.4, 118.7, 112.8, 109.7, 51.8, 38.0, 32.8, 24.6. HRMS (ESI-TOF) Calcd. For C₃₂H₂₇BrN₃O ([M+H]⁺): 548.1332, found: 548.1320.



***Trans*-(6-(1-methyl-1*H*-indol-3-yl)-3-phenyl-5-(*o*-tolyl)-5,6-dihydropyridazin-1(4*H*)-yl)-(phenyl)methanone (3r):**


Yield (72%); 69 mg; White solid; m.p. 194-196 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.79 (d, *J* = 7.9 Hz, 1H), 7.62 (dd, *J* = 10.4, 6.6 Hz, 4H), 7.36 (dt, *J* = 14.2, 7.0 Hz, 3H), 7.30 – 7.19 (m, 6H), 7.17 – 7.06 (m, 4H), 6.71 (s, 1H), 6.17 (s, 1H), 4.10 (d, *J* = 6.7 Hz, 1H), 3.59 (s, 3H), 2.84 (dd, *J* = 18.4, 6.7 Hz, 1H), 2.77 (d, *J* = 18.3 Hz, 1H), 2.63 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 170.4, 147.3, 140.7, 137.6, 137.1, 135.6, 135.3, 131.0, 130.3, 130.0, 129.4, 128.5, 127.4, 127.2, 126.7, 126.6, 125.6, 125.4, 125.3, 121.9, 119.4, 119.1, 113.4, 109.7, 50.4, 34.9, 32.9, 25.4, 20.6. HRMS (ESI-TOF) Calcd. For C₃₃H₃₀N₃O ([M+H]⁺): 484.2383, found: 484.2373.



***Trans*-5-methyl-6-(1-methyl-1*H*-indol-3-yl)-3-phenyl-5,6-dihydropyridazin-1(4*H*)-yl(phenyl)methanone (3s):**


Yield (82%); 66 mg; White solid; m.p. 153-155 °C; 1.5:1 dr; major: ¹H NMR (400 MHz, Chloroform-*d*) δ 7.83 (s, 1H), 7.74 (d, *J* = 6.6 Hz, 2H), 7.62 – 7.57 (m, 2H), 7.44 – 7.39 (m, 3H), 7.33 – 7.29 (m, 3H), 7.20 (s, 1H), 7.16 – 7.09 (m, 2H), 6.69 (s, 1H), 6.07 (s, 1H), 3.62 (s, 3H), 2.74 (d, *J* = 19.3 Hz, 1H), 2.38 (dd, *J* = 17.4, 5.7 Hz, 2H), 1.26 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 170.6, 146.8, 137.6, 136.5, 135.4, 130.0, 129.9, 129.1, 128.3, 127.4, 126.6, 125.5, 125.4, 121.8, 119.4, 119.0, 113.6, 109.5, 50.0, 32.7, 27.9, 26.6, 18.9. minor: ¹H NMR (400 MHz, Chloroform-*d*) δ 7.76 (s, 1H), 7.62 – 7.58 (m, 2H), 7.57 (s, 1H), 7.39 (t, *J* = 7.9 Hz, 3H), 7.29 – 7.26 (m, 2H), 7.18 (dd, *J* = 8.0, 3.6 Hz, 4H), 7.11 (d, *J* = 8.4 Hz, 1H), 6.66 (s, 1H), 6.14 (s, 1H), 3.57 (s, 3H), 2.74 (d, *J* = 17.0 Hz, 1H), 2.45 (dd, *J* = 17.8, 6.1 Hz, 2H), 0.98 (d, *J* = 6.4 Hz, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 169.5, 145.6, 137.6, 137.2, 135.6, 130.2, 129.9, 129.1, 128.4, 127.9, 127.2, 125.7, 125.3, 121.6, 119.6, 119.1,

111.5, 109.2, 52.1, 32.7, 28.1, 27.5, 18.4. HRMS (ESI-TOF) Calcd. For $C_{27}H_{25}N_3ONa$ ($[M+Na]^+$): 430.1890, found: 430.1881.




Trans-(6-(4-bromo-1-methyl-1H-indol-3-yl)-3,5-diphenyl-5,6-dihydropyridazin-1(4H)-yl)(phenyl)methanone (3t):

Yield (78%); 85 mg; White solid; m.p. 236-237 °C; 1H NMR (400 MHz, Chloroform-*d*) δ 7.62 – 7.58 (m, 4H), 7.40 – 7.32 (m, 5H), 7.28 – 7.22 (m, 6H), 7.14 (d, $J = 5.4$ Hz, 2H), 7.00 (t, $J = 7.9$ Hz, 1H), 6.85 (s, 1H), 6.71 (s, 1H), 4.08 (d, $J = 6.7$ Hz, 1H), 3.54 (s, 3H), 2.89 (d, $J = 18.2$ Hz, 1H), 2.74 (dd, $J = 18.2, 6.9$ Hz, 1H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 170.1, 146.4, 142.1, 138.8, 137.1, 135.2, 130.3, 130.0, 129.3, 128.7, 128.5, 127.6, 127.4, 127.03, 127.01, 125.5, 124.3, 123.9, 122.8, 114.7, 113.9, 108.8, 50.6, 38.8, 33.1, 24.8. HRMS (ESI-TOF) Calcd. For $C_{32}H_{26}BrN_3ONa$ ($[M+Na]^+$): 570.1151, found: 570.1141.




Trans-(6-(6-chloro-1-methyl-1H-indol-3-yl)-3,5-diphenyl-5,6-dihydropyridazin-1(4H)-yl)(phenyl)methanone (3u):

Yield (78%); 78 mg; White solid; m.p. 206-208 °C; 1H NMR (400 MHz, Chloroform-*d*) δ 7.71 – 7.65 (m, 5H), 7.50 – 7.39 (m, 3H), 7.37 – 7.32 (m, 7H), 7.30 – 7.25 (m, 2H), 7.18 – 7.15 (m, 1H), 6.75 (s, 1H), 6.31 (s, 1H), 3.94 (d, $J = 7.5$ Hz, 1H), 3.62 (s, 3H), 2.96 (d, $J = 18.3$ Hz, 1H), 2.81 (dd, $J = 18.3, 7.1$ Hz, 1H). ^{13}C NMR (100 MHz, Chloroform-*d*) δ 170.4, 146.4, 142.1, 138.1, 137.0, 135.1, 130.4, 130.0, 129.5, 129.0, 128.6, 128.3, 127.5, 127.3, 126.9, 126.8, 125.6, 123.8, 120.1, 119.8, 113.6, 109.8, 51.9, 38.6, 33.0, 24.7. HRMS (ESI-TOF) Calcd. For $C_{32}H_{27}ClN_3O$ ($[M+H]^+$): 504.1837, found: 504.1830.




***Trans*-(6-(5-bromo-1-methyl-1*H*-indol-3-yl)-3,5-diphenyl-5,6-dihydropyridazin-1(4*H*)-yl)(phenyl)methanone (3v):**

Yield (83%); 90 mg; White solid; m.p. 246-248 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.92 (s, 1H), 7.68 – 7.66 (m, 4H), 7.49 – 7.33 (m, 11H), 7.28 – 7.25 (m, 1H), 7.16 (d, *J* = 8.7 Hz, 1H), 6.74 (s, 1H), 6.29 (s, 1H), 3.94 (d, *J* = 7.4 Hz, 1H), 3.63 (s, 3H), 2.97 (d, *J* = 18.4 Hz, 1H), 2.80 (dd, *J* = 18.3, 7.1 Hz, 1H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 170.3, 146.4, 141.9, 137.0, 136.4, 135.0, 130.4, 130.0, 129.5, 129.0, 128.6, 127.5, 127.4, 127.3, 126.90, 126.88, 125.6, 125.0, 121.5, 112.94, 112.88, 111.3, 51.8, 38.4, 33.0, 24.8. HRMS (ESI-TOF) Calcd. For C₃₂H₂₇BrN₃O ([M+H]⁺): 548.1332, found: 548.1319.



***Trans*-(6-(1,5-dimethyl-1*H*-indol-3-yl)-3,5-diphenyl-5,6-dihydropyridazin-1(4*H*)-yl)-(phenyl)methanone (3w):**

Yield (74%); 71 mg; White solid; m.p. 192-194 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.67 (t, *J* = 6.8 Hz, 4H), 7.58 (s, 1H), 7.47 – 7.36 (m, 6H), 7.35 – 7.32 (m, 4H), 7.25 (t, *J* = 7.1 Hz, 1H), 7.18 (d, *J* = 8.3 Hz, 1H), 7.09 (d, *J* = 6.9 Hz, 1H), 6.70 (s, 1H), 6.35 (s, 1H), 4.00 (d, *J* = 7.2 Hz, 1H), 3.61 (s, 3H), 2.94 (d, *J* = 18.2 Hz, 1H), 2.83 (dd, *J* = 18.3, 6.9 Hz, 1H), 2.52 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 170.2, 146.2, 142.3, 137.1, 136.1, 135.2, 130.2, 129.9, 129.3, 128.9, 128.53, 128.45, 127.3, 127.1, 126.9, 126.0, 125.5, 125.4, 123.6, 118.5, 112.6, 109.4, 52.0, 38.2, 32.8, 24.7, 21.6. HRMS (ESI-TOF) Calcd. For C₃₃H₃₀N₃O ([M+H]⁺): 484.2383, found: 484.2375.




***Trans*-6-(5-methoxy-1-methyl-1*H*-indol-3-yl)-3,5-diphenyl-5,6-dihydropyridazin-1(4*H*)-yl)-(phenyl)methanone (3x):**

Yield (80%); 79 mg; White solid; m.p. 192-194 °C; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.69 – 7.65 (m, 4H), 7.50 – 7.39 (m, 4H), 7.37 – 7.32 (m, 7H), 7.23 – 7.22 (m, 1H), 7.19 (d, *J* = 8.8 Hz, 1H), 6.94 – 6.92 (m, 1H), 6.74 (s, 1H), 6.32 (s, 1H), 3.96 (d, *J* = 7.1 Hz, 1H), 3.89 (s, 3H), 3.64 (s, 3H), 2.96 (d, *J* = 18.3 Hz, 1H), 2.86 (dd, *J* = 18.3, 6.9 Hz, 1H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 170.4, 154.0, 146.4, 142.4, 137.1, 135.3, 133.1, 130.3, 130.0, 129.4, 129.0, 128.5, 127.4, 127.2, 127.0, 126.9, 126.6, 125.5, 112.8, 112.1, 110.5, 101.1, 56.1, 52.0, 38.5, 33.0, 24.9. HRMS (ESI-TOF) Calcd. For C₃₃H₃₀N₃O₂ ([M+H]⁺): 500.2333, found: 500.2320.

III. Optimization reaction conditions for the asymmetric IEDDA cyclization

As shown in Table S1, a series of chiral oxazoline ligands was firstly examined in the Cu-catalyzed inverse-electron-demand aza-Diels-Alder (IEDDA) reaction between *in situ* generated azoalkene and 3-vinylindole **1a** in the presence of Na₂CO₃, and ligand **L3** could deliver the desired product **opt-3a** with the best result in 72% yield and 75% ee (entry 3). Subsequently, the solvent effect was investigated in the Cu(OTf)₂/**L3** catalytic system, this transformation was proceeded smoothly in several solvents, such as THF, MeCN and DCE (entries 5-7), and high yield and good enantioselectivity was given in MeCN (entry 6, 96% yield, 89% ee). It was found that another metal precursor Cu(MeCN)₄BF₄ also can provide similar reaction result with Cu(OTf)₂ (entry 9 vs entry 6, 93% yield, 89% ee). In addition, when the azoalkene was generated *in situ* from (*Z*)-*N'*-(2-chloro-1-phenylethylidene)benzohydrazide in the presence of Na₂CO₃, good yield and better enantioselectivity was afforded (entry 10, 81% yield, 93% ee). Some bases, such as NaHCO₃, K₂CO₃ and K₃PO₄, were also inspected into this asymmetric cycloaddition reaction, poor to good reaction results could be provided (entries 11-13, 32-82% yields, 15%-89% ee).


Table S1. Optimization reaction conditions for the asymmetric IEDDA cyclization.^a



entry	ligand	[Cu]	X	base	solvent	yield (%) ^b	ee (%) ^c
1	L1	Cu(OTf) ₂	Br	Na ₂ CO ₃	DCM	75	21
2	L2	Cu(OTf) ₂	Br	Na ₂ CO ₃	DCM	76	30
3	L3	Cu(OTf) ₂	Br	Na ₂ CO ₃	DCM	72	75
4	L4	Cu(OTf) ₂	Br	Na ₂ CO ₃	DCM	57	19
5	L3	Cu(OTf) ₂	Br	Na ₂ CO ₃	THF	75	0
6	L3	Cu(OTf) ₂	Br	Na ₂ CO ₃	MeCN	96	89
7	L3	Cu(OTf) ₂	Br	Na ₂ CO ₃	DCE	91	31
8	L3	(CuOTf•1/2Ph) ₂	Br	Na ₂ CO ₃	MeCN	67	73
9	L3	Cu(MeCN) ₄ BF ₄	Br	Na ₂ CO ₃	MeCN	93	89
10	L3	Cu(OTf) ₂	Cl	Na ₂ CO ₃	MeCN	81	93
11	L3	Cu(OTf) ₂	Cl	NaHCO ₃	MeCN	82	89
12	L3	Cu(OTf) ₂	Cl	K ₂ CO ₃	MeCN	76	73
13	L3	Cu(OTf) ₂	Cl	K ₃ PO ₄	MeCN	32	15

^a Reaction conditions: **1a** (0.14 mmol), **2a** (0.10 mmol), [Cu] (0.010 mmol), ligand (0.012 mmol), base (0.24 mmol) in 1 mL solvent at room temperature for 24 h. The dr value was determined by the crude ¹H NMR analysis. ^b Yield was obtained after chromatographic purification. ^c The ee value was determined by HPLC analysis.


IV. Gram-scale inverse-electron-demand aza-Diels-Alder reaction



A flame dried Schlenk tube was cooled to room temperature and filled with N₂. 3-vinylindole **1a** (5.6 mmol), the azoalkene generating *in situ* from benzohydrazide **2g** (4.0 mmol), Na₂CO₃ (9.6 mmol) and CH₃CN (40 mL) were added into the Schlenk tube and filled with N₂ at room temperature. TLC analysis indicated completion of the reaction after about 30 h. Then the reaction mixture was


concentrated *in vacuo* to obtain the crude product. The crude product was purified by flash silica gel chromatography to afford the product **3g** in 72% yield (1.32 g).

V. Synthetic transformation



To a solution of **3g** (0.2 mmol) in 1 mL CH₂Cl₂ was added CF₃COOH (0.6 mmol) at room temperature, and the corresponding mixture was stirred at this temperature until the reaction completed (monitoring by TLC). The solvent was removed under reduced pressure and the residue was purified by column chromatography (PE:EA = 3:1) on silica gel to afford desired compound **4** in 62% yield.


To a solution of **3v** (0.10 mmol) in THF/H₂O (4:1 v/v) was added Pd(PPh₃)₄ (0.01 mmol), phenylboronic acid (0.20 mmol) and K₂CO₃ (20.7 mg, 0.15 mmol). The resulting mixture was stirred at 100 °C for 24 h under argon atmosphere. After the completion of the reaction which was indicated by TLC, water (5 mL) was added to the reaction mixture, which was then extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried and concentrated under the reduced pressure to give a residue. Finally, the residue was purified by preparative thin layer chromatography (PE:DCM = 1:1) on silica gel to afford pure product **5** in 80% yield.



Trans-3-(4,6-diphenyl-2,3,4,5-tetrahydropyridazin-3-yl)-1-methyl-1H-indole (4):

Yield (62%); 45 mg; Yellow liquid; ¹H NMR (400 MHz, Chloroform-*d*) δ 7.74 (d, *J* = 7.1 Hz, 2H), 7.68 (d, *J* = 7.9 Hz, 1H), 7.36 (t, *J* = 7.3 Hz, 2H), 7.29 (t, *J* = 8.0 Hz, 2H), 7.19 – 7.15 (m, 4H), 7.12 – 7.04 (m, 4H), 6.83 (s, 1H), 4.57 (d, *J* = 9.7 Hz, 1H), 3.61 (s, 3H), 3.06 (dd, *J* = 18.2, 6.4 Hz, 1H), 2.91


(dd, $J = 18.2, 10.0$ Hz, 1H). ^{13}C NMR (100 MHz, Chloroform- d) δ 143.7, 143.0, 138.1, 137.0, 128.5, 128.4, 127.9, 127.69, 127.65, 126.61, 126.60, 124.5, 121.6, 119.6, 119.1, 112.7, 109.3, 55.4, 43.1, 32.7, 32.0. HRMS (ESI-TOF) Calcd. For $\text{C}_{25}\text{H}_{24}\text{N}_3$ ($[\text{M}+\text{H}]^+$): 366.1965, found: 366.1957.



***Trans*-(6-(1-methyl-5-phenyl-1H-indol-3-yl)-3,5-diphenyl-5,6-dihydropyridazin-1(4H)-yl)(phenyl)methanone (5):**

Yield (80%); 44 mg; White solid; m.p. 214-216 °C; ^1H NMR (400 MHz, Chloroform- d) δ 7.98 (s, 1H), 7.69 (d, $J = 6.9$ Hz, 6H), 7.54 – 7.38 (m, 7H), 7.38 – 7.31 (m, 8H), 7.28 – 7.25 (m, 1H), 6.79 (s, 1H), 6.42 (s, 1H), 4.03 (d, $J = 7.1$ Hz, 1H), 3.69 (s, 3H), 2.97 (d, $J = 18.3$ Hz, 1H), 2.87 (dd, $J = 18.3, 6.9$ Hz, 1H). ^{13}C NMR (100 MHz, Chloroform- d) δ 170.4, 146.4, 142.5, 142.2, 137.3, 137.1, 135.2, 133.1, 130.4, 130.0, 129.4, 129.0, 128.8, 128.6, 127.6, 127.4, 127.3, 126.9, 126.8, 126.5, 125.7, 125.6, 122.1, 117.5, 113.7, 110.0, 52.0, 38.6, 33.0, 24.9. HRMS (ESI-TOF) Calcd. For $\text{C}_{38}\text{H}_{32}\text{N}_3\text{O}$ ($[\text{M}+\text{H}]^+$): 546.2467, found: 546.2520.

VI. The configuration determination of *trans*-3b



In a 10 mL oven-dried glass sample vial, 40 mg pure **3b** and 1.0 mL CH_2Cl_2 were added, and then 3 mL *n*-hexane was slowly added to the solution, which was sealed with perforated paper at room temperature to grow crystals.³

Bond precision: C-C = 0.0077 Å

Wavelength = 0.71073

Cell: a = 10.973(3)

b = 27.895(9)

c = 9.090(3)

	alpha = 90	beta = 112.891(6)	gamma = 90
Temperature:	200 K		
	Calculated		Reported
Volume	2563.3(14)		2563.3(14)
Space group	P 21/c		P 1 21/c 1
Hall group	-P 2ybc		-P 2ybc
Moiety formula	C33 H29 N3 O2		C33 H29 N3 O2
Sum formula	C33 H29 N3 O2		C33 H29 N3 O2
Mr	499.59		499.59
Dx,g cm-3	1.295		1.295
Z	4		4
Mu (mm-1)	0.081		0.081
F000	1056.0		1056.0
F000'	1056.41		
h,k,lmax	13,33,10		13,33,10
Nref 4514			4384
Tmin,Tmax	0.994, 0.996		0.511, 0.745
Tmin'	0.992		
Correction method = #	Reported	T	Limits: Tmin = 0.511 Tmax = 0.745
AbsCorr = MULTI-SCAN			
Data completeness = 0.971			Theta(max) = 25.000
R(reflections) = 0.1067(3111)			wR2(reflections) = 0.2845(4384)
S = 1.193			Npar = 345



VII. Reference



1. Gao H.-Y.; Wu X.-X.; Zhang J.-L. Gold(I)-Catalyzed, Highly Diastereoselective, Tandem Heterocyclizations/[3+2] Cycloadditions: Synthesis of Highly Substituted Cyclopenta[c]furans. *Chem. Eur. J.* **2011**, *17*, 2838.
2. Chen J.-R.; Dong W.-R.; M. Candy; Pan F.-F.; M. Jörres; C. Bolm. Enantioselective Synthesis of



Dihydropyrazoles by Formal [4+1] Cycloaddition of in Situ-Derived Azoalkenes and Sulfur Ylides. *J. Am. Chem. Soc.* **2012**, *134*, 6924.

3. CCDC 2077849 (**3b**) contains the supplementary crystallographic data for this paper.

VIII. ¹H NMR and ¹³C NMR spectra














7.8200
7.8003
7.6846
7.6787
7.6689
7.6602
7.5539
7.3911
7.3838
7.3749
7.3549
7.3484
7.3401
7.3185
7.2944
7.2776
7.2574
7.2501
7.2276
7.2232
7.2076
6.7286
6.3444





4.0121
3.9939
3.607
2.9862
2.9403
2.8678
2.8502
2.8220
2.8044



169.2524
147.0549
142.1600
137.6985
136.9214
134.0488
131.7406
130.6757
129.6231
128.9771
128.6638
127.3111
126.8587
125.9738
125.5616
125.2328
124.9171
122.1422
119.4732
118.9189
113.0750
109.7684
52.3245
38.4808
32.8693
24.7479











7.9421
7.9222
7.7825
7.7646
7.4501
7.4348
7.4163
7.3955
7.3666
7.3562
7.3419
7.3269
7.3101
7.2896
7.2817
7.2496
7.2298
7.2131
6.8649
-5.9597



3.8690
3.8519
3.7018
2.8685
2.8230
2.8003
2.7834
2.7548
2.7407



-1.4304



153.3963
146.0807
142.8502
137.6357
137.3920
128.9783
128.7261
128.2884
126.9290
126.8844
126.0441
125.4683
125.1898
121.8001
119.1904
118.5727
114.4370
109.5648
81.3030
77.2023
53.4254
38.7507
32.6658
26.0540
24.4095













7.8179
7.7983
7.6499
7.6315
7.5282
7.5062
7.4789
7.4669
7.4308
7.4116
7.3943
7.3616
7.3497
7.3102
7.3003
7.2840
7.2763
7.2296
7.2256
7.2131
7.2095
6.7937
6.7297
-6.3570



4.0230
4.0053
3.6789
2.9135
2.8679
2.8255
2.8083
2.7799
2.7626



170.3565
145.3289
142.0851
137.7275
135.9668
135.1113
131.6792
130.3993
129.8512
128.9778
127.4539
127.3154
127.0493
126.8237
125.9628
125.1791
123.7279
122.1203
119.4416
118.9218
113.0935
109.7431
52.1648
38.3700
32.8548
24.6074











7.8310
7.8115
7.7005
7.6815
7.6702
7.6652
7.6558
7.6466
7.4608
7.4432
7.4300
7.4111
7.3439
7.3375
7.3281
7.2809
7.2652
7.2450
7.2329
7.2247
7.2145
7.1338
7.1143
7.0653
7.0466
6.3446



3.9802
3.9621
3.6365
2.9311
2.8853
2.8405
2.8231
2.7949
2.7774
2.3512









170.2894
146.4700
142.3044
138.4040
137.6499
137.1249
135.2688
130.2187
129.8759
129.2773
128.7093
128.4470
127.9431
127.8069
127.3497
125.9980
125.4820
125.2054
123.5254
121.9569
119.2852
118.9242
113.1778
109.6317



52.0549
38.3984
32.7430
24.8457
21.5586














7.8019
7.7821
7.6403
7.6169
7.6074
7.5977
7.3996
7.3819
7.3653
7.3470
7.2900
7.2845
7.2765
7.2724
7.2218
7.2122
7.1928
7.1588
7.1377
7.1338
7.1176
7.1008
7.0861
7.0765
6.9888
6.9888
-6.1704
4.1074
4.0906
-3.5895
2.8676
2.8508
2.8215
2.8048
2.7910
2.7452
2.6270





7.8257
7.7455
7.7291
7.7131
7.6029
7.5935
7.5842
7.4364
7.4300
7.4193
7.4109
7.3916
7.3162
7.3094
7.3004
7.2049
7.1499
7.1375
7.1182
7.1019
-6.6857

-6.0655

-3.6222

2.7616
2.7133
2.4065
2.3905
2.3614
2.3487



1.2724
1.2554




170.5537
146.8294
137.6441
136.4652
135.4227
130.0140
129.9229
129.0692
128.5334
127.3522
126.6179
125.4536
125.3708
121.7894
119.4087
119.0286
113.5570
109.4835

-50.0488


-32.6882
-27.8786
-26.6107
-18.9433





7.7612
7.6161
7.6080
7.5988
7.5890
7.5881
7.4124
7.3910
7.3731
7.2789
7.2711
7.2637
7.1921
7.1830
7.1721
7.1630
7.1253
7.1044
-6.6572
-6.1443





-3.5650
2.7631
2.7206
2.4787
2.4635
2.4344
2.4191
0.9927
0.9767





169.4532
145.6395
137.5937
137.1884
135.5848
130.1929
129.9448
129.1061
128.4359
127.9284
127.2070
125.6913
125.2592
121.6408
119.5638
119.0671
111.5208
109.2296
52.1185
32.7339
28.1274
27.5103
18.3715







7.7147
7.6935
7.6788
7.6737
7.6647
7.6604
7.6540
7.4713
7.4534
7.4327
7.4177
7.4134
7.3594
7.3551
7.3521
7.3466
7.2978
7.2933
7.2529
7.2313
7.1771
7.1565
7.1368
6.3132

3.9502
3.9315
3.6224
2.9827
2.9369
2.8374
2.8196
2.7737





170.3818
146.4229
142.0624
138.0990
136.9990
135.0671
130.4283
129.9808
129.4958
128.9863
128.5723
128.2560
127.4679
127.3441
126.8772
126.8267
125.5575
123.8383
120.1417
119.8301
113.6332
109.7989
51.9234
38.6271
32.9502
24.7385





7.9189
7.6792
7.6742
7.6612
7.6551
7.4874
7.4689
7.4510
7.4297
7.4107
7.3932
7.3849
7.3702
7.3643
7.3540
7.3411
7.3317
7.3270
7.2784
7.2724
7.2640
7.2567
7.2487
7.1712
-6.7439
-6.2815

3.9509
3.9324
3.6285
2.9937
2.9478
2.8360
2.8181
2.7902
2.7724





170.3443
146.4152
141.9310
136.9983
135.3733
135.0414
130.4434
130.0013
129.5028
128.9966
128.5765
127.4612
127.3595
127.3252
126.8965
125.5629
124.9818
121.5078
112.8455
112.8821
111.2597

51.8476
38.4305
33.0369
24.7555





7.6831
7.6675
7.6491
7.5822
7.4531
7.4356
7.4205
7.4028
7.3816
7.3665
7.3446
7.3381
7.3291
7.2628
7.2452
7.2275
7.1903
7.1895
7.0976
7.0805
-6.6962
-6.3531

4.0103
3.9924
-3.6093
2.9611
2.9156
2.8633
2.8459
2.8176
2.8003
2.5248





170.2381
146.2246
142.2621
137.1010
136.0893
135.2355
130.1970
129.8945
129.2864
128.8451
128.5330
128.4521
127.3315
127.1284
126.8589
126.0209
125.4734
125.3856
123.6063
118.5236
112.5622
109.3565
-52.0001
-38.2453
-32.7716
-24.7021
-21.5963





7.6848
7.6785
7.6691
7.6600
7.4674
7.4496
7.4315
7.4128
7.3955
7.3652
7.3598
7.3565
7.3503
7.3429
7.3389
7.3291
7.2275
7.2215
7.2040
7.1819
6.9444
6.9384
6.9222
6.9162
6.7474

3.9882
3.9505
3.8883
3.6363
2.9804
2.9348
2.8921
2.8749
2.8465
2.8292





170.3664
154.0201
146.9676
142.3517
137.1186
135.2700
133.0869
130.2943
129.9567
129.3971
128.9626
128.5331
127.4147
127.2386
127.0000
126.9029
126.6408
125.5414
112.8101
112.0545
110.4713
101.1190
56.0906
51.9541
38.4554
33.0086
24.8538





7.7557
7.7517
7.7339
7.6954
7.6755
7.3870
7.3826
7.3695
7.3650
7.3500
7.3205
7.2943
7.2843
7.2336
7.1995
7.1924
7.1758
7.1605
7.1062
7.0850
7.0815
7.0685
7.0650
7.0617
7.0485
7.0450
6.8375



4.5909
4.5667

3.6370
3.1023
3.0863
3.0567
3.0407
2.9596
2.9345
2.9142
2.8890




143.7340
143.0443
138.1489
137.0458
128.4747
128.3633
127.9434
127.6873
127.6543
126.6117
126.5999
124.5009
121.6419
119.6409
119.1016
112.7399
109.3126






IX. HPLC spectra



Data File E:\DATA\CTT\CTT\CTT-3A 2021-01-25 19-46-02\CTT-3a1.D
 Sample Name: ctt-3a-rac

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    2
Acq. Instrument : 1260                        Location  :   31
Injection Date  : 1/25/2021 7:54:09 PM        Inj       :    1
                                           Inj Volume: 15.000 µl
Acq. Method     : E:\DATA\CTT\CTT\CTT-3A 2021-01-25 19-46-02\IE-60-40-1.2mL-15ul-alInm40min.M
Last changed    : 1/25/2021 7:46:02 PM by SYSTEM
Analysis Method : E:\DATA\CTT\CTT\CTT-3A 2021-01-25 19-46-02\IE-60-40-1.2mL-15ul-alInm40min.M (Sequence Method)
Last changed    : 1/28/2021 7:38:02 PM by SYSTEM
                 (modified after loading) (Current integration events modified)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```


=====
Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1.D, Sig=230,4 Ref=360,100

Peak #	Ret Time [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	28.656	BB	1.1053	7886.20508	109.09609	50.0699
2	34.233	BB	1.2156	7864.18555	94.04229	49.9301

Totals : 1.57504e4 203.13838


*** End of Report ***



Data File: E:\DATA\CTT\CTT\CTT-3A 2021-01-25 19-46-02\CTT-3a2.D
 Sample Name: ctt-3a-opt

```

=====
Acq. Operator   : SYSTEM                      Seq. Line :    3
Acq. Instrument : 1260                       Location  :   32
Injection Date  : 1/25/2021 8:35:07 PM       Inj       :    1
                                           Inj Volume: 15.000 µl
Acq. Method     : E:\DATA\CTT\CTT\CTT-3A 2021-01-25 19-46-02\IE-60-40-1.2mL-15ul-alInm-40min.M
Last changed    : 1/25/2021 7:46:02 PM by SYSTEM
Analysis Method : E:\DATA\CTT\CTT\CTT-3A 2021-01-25 19-46-02\IE-60-40-1.2mL-15ul-alInm-40min.M (Sequence Method)
Last changed    : 1/28/2021 7:38:02 PM by SYSTEM
                 (modified after loading) (Current integration events modified)
Additional Info : Peak(s) manually integrated
  
```



Area Percent Report

```

Sorted By      : Signal
Multiplier     : 1.0000
Dilution       : 1.0000
Do not use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1.D, Sig=230,4 Ref=360,100

Peak #	Ret Time [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	28.662	BB	0.7849	674.79413	10.21168	3.2908
2	34.035	BB	1.2690	1.98307e4	234.87126	96.7092

Totals : 2.05055e4 245.08294

*** End of Report ***